BlackRock Amends Recursion Pharma Stake, Signals Continued Confidence
Ticker: RXRX · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still holds Recursion Pharma stock, signaling long-term confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating its ownership of Class A Common Stock in Recursion Pharmaceuticals, Inc. as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, but passive, investment in the biotech company. This matters to investors because BlackRock is a major institutional investor, and their continued stake signals confidence in Recursion Pharmaceuticals' long-term prospects, potentially influencing other investors.
Why It Matters
BlackRock's updated filing confirms their ongoing substantial, passive investment in Recursion Pharmaceuticals, which can be seen as a vote of confidence from a major institutional player.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate change in company operations or significant new risks.
Analyst Insight
Investors should note BlackRock's continued passive stake as a sign of institutional confidence, but also recognize this is a routine update and not an active investment decision change. Further research into Recursion Pharmaceuticals' fundamentals and recent performance is always recommended.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Recursion Pharmaceuticals, Inc. (company) — the subject company whose Class A Common Stock is being reported
- January 29, 2024 (date) — the date the SC 13G/A amendment was filed
- December 31, 2023 (date) — the date of the event which required the filing of this statement
- Class A Common Stock (other) — the type of securities held by BlackRock Inc.
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'subject company' in this filing?
The subject company is RECURSION PHARMACEUTICALS, INC., with a Central Index Key (CIK) of 0001601830.
Who is the 'filed by' entity in this document?
The filing entity is BlackRock Inc., with a Central Index Key (CIK) of 0001364742.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Class A Common Stock of Recursion Pharmaceuticals, Inc. is 75629V104.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding RECURSION PHARMACEUTICALS, INC. (RXRX).